@?Interferon beta-1A for multiple sclerosis

Drug and Therapeutics Bulletin

Volumn 36, Issue 1, 1998, Pages 7-8

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; PARACETAMOL;

ADOLESCENT; ADULT; ASTHENIA; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; FEVER; HEADACHE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MYALGIA; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SEIZURE; SHORT SURVEY; SUICIDE; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0031965368     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.1998.3617     Document Type: Short Survey

References (6)

1. Interferon beta-1b - hope or hype? DTB 1996; 34: 9-11.
2. Interferon beta-1a. Summary of product characteristics, France. Biogen, March 1997.
3. Jacobs LD, Cookfair DL, Rudick RA et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis design and conduct of study and baseline characteristics of patients. Mult Scler 1995; 1: 118-35
4. Jacobs LD, Cookfair DL, Rudick RA et al Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
5. Goodkin DE, Cookfair D, Wende K et al. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurology 1992; 42: 859-63.
6. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler 1995; 1: 37-47.